A Daily Network publication
Explore the network
Private Wealth Daily
Independent Intelligence on the Private Wealth Industry
Friday, October 2, 2026The Morning Brief →Sign in
GNOMGlobal XINDEX

Global X Genomics & Biotechnology ETF

$68.78-2.41% vs prior close
407052-WK

Price through Oct 1 · Flows through Aug 23. Figures use the latest available records, not a live quote. Fund details retrieved Oct 1. Holdings snapshot retrieved Oct 1.

The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, "Genomics & Biotechnology Companies"), as defined by Solactive AG, the provider of the underlying index. The fund is non-diversified.

Price & daily flows
63.955.246.568.78DAILY NET FLOWOct 1Jan 30Jun 1Oct 1

SOURCE: MARKET TAPE & DAILY CREATION/REDEMPTION RECORDS · 1Y SHOWN

The desk’s read

Recent fund-flow records are unavailable, while the price has returned +51.3% so far this year. At 0.50% a year it is not the cheapest way in — FDHT has a reported fee of 0.39%.

COMPOSED FROM THE FUND’S OWN DAILY RECORDS · UPDATED WITH EACH REFRESH

$85Massets under management
0.50%expense ratio · $50 per $10,000 a year
—net flow, trailing month
36Kavg daily volume, 30 days
41holdings · US-domiciled
2019listed April 5, 2019 · beta 1.20
The book at a glance
MRNA-1.9%TWST-2.7%TXG-1.8%ILMN-2.9%NTRA-1.2%GH-2.0%TECH-0.1%VRTX-3.1%BMRN-2.6%QGEN-3.9%CRSP+0.2%VCYT-4.0%BNTX-1.5%CAI-7.4%ARWR-1.0%PRAX-1.5%CDNA+1.9%LEGN-2.9%LLY-0.6%BEAM-0.2%GILD-1.0%BLLN-0.6%WGS-1.9%SRPT-3.6%AZN-2.3%RARE-1.9%NTLA+0.5%DHR-4.4%VIR+1.0%QURE-3.3%BMY-1.5%STOK+0.0%PSNL

CELL SIZE IS PORTFOLIO WEIGHT · COLOR IS THE CHANGE IN THE LATEST AVAILABLE SNAPSHOT · TOP 40 POSITIONS

HoldingsDownload CSV
#HoldingWeightPriceDay52-wk
1MRNAMODERNA9.45%$188.94-1.9%
2TWSTTWIST BIOSCIENCE8.10%$188.05-2.7%
3TXG10X GENOMICS7.29%$88.76-1.8%
4ILMNILLUMINA5.72%$265.72-2.9%
5NTRANATERA5.43%$408.47-1.2%
6GHGUARDANT HEALTH5.44%$174.75-2.0%
7TECHBIO-TECHNE3.38%$72.40-0.1%
8VRTXVERTEX PHARMACEUTICALS3.26%$506.74-3.1%
9BMRNBIOMARIN PHARMACEUTICAL3.02%$58.44-2.6%
10QGENQIAGEN NV2.99%$42.04-3.9%
11CRSPCRISPR THERAPEUTICS AG2.68%$55.44+0.2%
12VCYTVERACYTE2.56%$44.19-4.0%
13BNTXBIONTECH SE2.47%$96.85-1.5%
14CAICaris Life Sciences2.63%$28.35-7.4%
15ARWRARROWHEAD PHARMACEUTICALS2.42%$64.79-1.0%

The full book, free with one sign-in.

Top 15 positions are open to everyone. Sign in once and every fund’s complete holdings — plus CSV export, watchlists, and flow alerts — unlock across the network.

Sign in to see all 41
Sector weights
Healthcare100%
Health Technology99.08%
Health Services0.75%
Miscellaneous0.15%
Other0.06%
PORTFOLIO COMPOSITION, LATEST DISCLOSURE
Country weights
United States92.49%
Hong Kong3.81%
Germany3.28%
China3.13%
Switzerland3.08%
Japan0.59%
Netherlands0.55%
Italy0.11%
PORTFOLIO COMPOSITION, LATEST DISCLOSURE
Performance
1 week-2.0%
1 month+6.2%
3 months+19.0%
6 months+66.2%
YTD+51.3%
1 year+72.5%
3 years—

PRICE RETURN, DISTRIBUTIONS NOT REINVESTED

Net flows
1 week—
1 month—
3 months—
YTD—
1 year—

CREATION/REDEMPTION DOLLARS, DAILY RECORDS

Monthly net flows
OctNovDecJanFebMarAprMayJunJulAug
DAILY CREATION/REDEMPTION RECORDS, TRAILING TWELVE MONTHS
The risk read
30%realized volatility, 30 days (annualized)
31%realized volatility, 1 year
-18.2%deepest fall from a peak, 1 year
-2.4%latest close versus that peak

The top holding is 9.4% of the book; the top ten carry 56%. Spread across 50+ names, it behaves like roughly 23 equally-weighted positions.

VOLATILITY & DRAWDOWN FROM THE DAILY TAPE · CONCENTRATION FROM THE LATEST DISCLOSED BOOK

Options tape
—calls · latest snapshot
—puts · latest snapshot
—put/call ratio
44Kshares traded
Most-traded holdings, options premiumBullishBearish
MRNA MODERNA$35M$34M
LLY ELI LILLY$30M$32M
NTRA NATERA$3M$6M
BMY BRISTOL MYERS SQUIBB$2M$3M
QGEN QIAGEN NV$2M$2M

TODAY’S OPTIONS PREMIUM IN THE FUND’S UNDERLYING NAMES

The case against GNOM

Due diligence cuts both ways. These funds sit on the same shelf and beat GNOM on at least one dimension that matters — the fee, the asset base, or where the money is going.

FundFeeAssetsFlow, 1MThe case
SPDW State Street SPDR Portfolio Developed World ex-US ETF0.03%$41.5B+$286M-47bp on fee · 490× the assets · +$286M in over the monthHead-to-head
BBUS JPMorgan BetaBuilders U.S. Equity ETF0.02%$9.4B+$187M-48bp on fee · 111× the assets · +$187M in over the monthHead-to-head
SPMD State Street SPDR Portfolio S&P 400 Mid Cap ETF0.03%$18.2B+$199M-47bp on fee · 215× the assets · +$199M in over the monthHead-to-head
SPYG State Street SPDR Portfolio S&P 500 Growth ETF0.04%$56.2B+$717M-46bp on fee · 663× the assets · +$717M in over the monthHead-to-head
SPTM State Street SPDR Portfolio S&P 1500 Composite Stock Market ETF0.03%$14.1B+$235M-47bp on fee · 167× the assets · +$235M in over the monthHead-to-head
Sign in to save this to The RecordA timestamped copy for the file — documentation, not advice.
InstrumentsHarvest substitutesTrade cost at $1MClient tearsheetStress this fund
Every weekday · 6:30 a.m. ET

The Morning Brief

The private wealth industry in four minutes, every weekday at 6:30 a.m. ET. Free.